Journey Medical Corporation Common Stock (DERM) is a publicly traded Healthcare sector company. As of May 21, 2026, DERM trades at $6.17 with a market cap of $172.09M and a P/E ratio of -16.63. DERM moved +0.08% today. Year to date, DERM is -13.34%; over the trailing twelve months it is -10.32%. Its 52-week range spans $3.54 to $9.56. Analyst consensus is strong buy with an average price target of $13.50. Rallies surfaces DERM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Journey Medical Reports Q1 Loss Narrowing From $0.18, Revenue Tops Forecasts: Journey Medical Corporation posted a Q1 net loss of $0.08 per share, down from a $0.18 loss a year earlier, while revenue outpaced analyst forecasts. Management highlighted year-over-year sales growth in core dermatology products and outlined supply-chain optimizations and marketing initiatives.
| Metric | Value |
|---|---|
| Price | $6.17 |
| Market Cap | $172.09M |
| P/E Ratio | -16.63 |
| EPS | $-0.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.56 |
| 52-Week Low | $3.54 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $64.68M |
| Net Income | $-9.59M |
| Gross Margin | 65.44% |
4 analysts cover DERM: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.50.